Zantac Cancer Lawsuits: Delaware Supreme Court to Hear Key Appeal

The highest court in Delaware has agreed to hear an appeal by GSK, Pfizer, Sanofi, and Boehringer Ingelheim seeking to end thousands of lawsuits alleging that the discontinued heartburn drug Zantac caused cancer, Reuters reports.

The drugmakers argue that the plaintiffs' expert testimony on the alleged cancer link is not supported by sound scientific methods. Without this testimony, the lawsuits cannot proceed.

The Delaware Supreme Court's decision to hear the appeal could significantly impact the future of the Zantac litigation. If the court upholds the lower court's ruling, the lawsuits could proceed to trial. However, if the court overturns the lower court's ruling, it could hinder the plaintiffs' ability to prove their claims.

The Zantac lawsuits in Delaware have not yet proceeded to trial, nor has any final judgment been rendered. In this state, the highest court only accepts appeals before a final judgment in cases with extraordinary or unusual circumstances.

From Blockbuster Drug to Cancer Concerns

Zantac, once a widely used heartburn remedy, was removed from shelves in 2020 due to worries about it possibly transforming into a cancer-causing agent. Initially given the green light by U.S. officials in 1983, Zantac achieved global top-selling status in 1988 and became a pioneer in exceeding $1 billion in yearly revenue. Over time, it was sold by four different companies, each now contending with numerous lawsuits.

Individuals taking legal action claim that Zantac exposure led to various cancers, such as gastric, bladder, and colorectal. The pharmaceutical companies involved have steadfastly refuted these claims, asserting that there is no scientific basis connecting Zantac to cancer.

If you or a loved one were diagnosed with certain cancers after taking Zantac or ranitidine, you may qualify for a FREE case review.

FILL OUT THE FORM ON THIS PAGE FOR MORE INFORMATION.

Key Legal Developments and Settlements In Zantac Litigation

The Zantac litigation has been ongoing for several years, with numerous legal battles and settlements taking place. In 2022, a federal judge in Florida rejected the plaintiffs' expert witnesses in about 50,000 cases, dealing a blow to the lawsuits. However, some of these cases are being appealed.

In addition, several drugmakers have agreed to settle with plaintiffs in individual cases or groups of cases. Sanofi has agreed to settle about 4,000 cases, while Pfizer has reportedly agreed to settle more than 10,000.

Earlier this month, three lawsuits alleging the heartburn drug causes cancer concluded in Cook County, Illinois. Two Illinois residents reached confidential settlements with the pharmaceutical company GSK, while another person dropped their case in early June.

Delaware Supreme Court to Decide the Fate of Zantac Lawsuits

The Delaware Supreme Court's decision to hear the appeal could significantly impact the future of the Zantac litigation. If the court upholds the lower court's ruling, the lawsuits could proceed to trial. However, if the court overturns the lower court's ruling, it could hinder the plaintiffs' ability to prove their claims.

If you or someone you care about has taken Zantac and subsequently developed cancer or tragically passed away, you might be eligible for compensation. Seeking advice from a legal professional who is knowledgeable about the ongoing litigation against Zantac manufacturers could provide you with the necessary guidance to pursue a claim.

CLICK HERE FOR A FREE CLAIM REVIEW FROM A ZANTAC LAWYER.